Skip to main content
Ion Beam Applications, SA logo

Ion Beam Applications, SA — Investor Relations & Filings

Ticker · IBAB ISIN · BE0003766806 LEI · 5493002RVRZ1S3CPUI26 BR Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2024-08-29 Interim / Quarterly Rep…
Country BE Belgium
Listing BR IBAB

About Ion Beam Applications, SA

https://www.iba-worldwide.com/

Ion Beam Applications (IBA) is a global company specializing in particle accelerator technology. It designs, manufactures, and markets advanced solutions for medical and industrial applications. The company is a leading supplier of proton therapy systems for the treatment of cancer. Its portfolio also includes dosimetry and quality assurance solutions for radiation therapy and medical imaging, as well as integrated systems for the production of radiopharmaceuticals (RadioPharma Solutions). Additionally, IBA provides industrial solutions, utilizing electron beam and X-ray accelerators for applications such as medical device sterilization and polymer modification.

Recent filings

Filing Released Lang Actions
240829-iba-hy24-results-en.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'IBA Reports Half Year 2024 Results' and contains detailed financial tables (Revenues, REBITDA, Net Result), an operating review, and business summaries for the first half of 2024. It provides substantive financial data and analysis rather than just an announcement of a report. Therefore, it is classified as an Interim/Quarterly Report. H1 2024
2024-08-29 English
240829-iba-hy24-results-fr.pdf
Earnings Release Classification · 98% confidence The document is a press release from IBA (Ion Beam Applications S.A.) announcing its consolidated financial results for the first half (S1) of 2024. It contains detailed financial tables, management commentary, operational reviews, and forward-looking statements. While it is an announcement of results, it provides the actual financial data and performance metrics for the interim period, which classifies it as an Earnings Release (ER) rather than a simple report publication announcement (RPA), as it contains the core financial highlights and performance data directly. H1 2024
2024-08-29 French
IFRS.report.mid-year.June-2024-FINAL_EN-SIGNED.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024' for Ion Beam Applications SA. It contains comprehensive financial statements (balance sheet, income statement, cash flow, etc.) for a six-month period, along with notes and an interim management report. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-08-29 English
IFRS.report.mid-year.June.2024-FINAL_FR-SIGNED.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for Ion Beam Applications SA (IBA) for the period ending June 30, 2024. It contains detailed consolidated financial statements (balance sheet, income statement, cash flow, etc.), notes to the financial statements, and a management report. It is not an announcement of a report (RPA) nor a simple earnings release (ER), as it provides full interim financial data and analysis. Therefore, it is classified as an Interim / Quarterly Report. H1 2024
2024-08-29 French
240827-IBA-2ProteusONE-Upenn-EN-final.pdf
Regulatory Filings Classification · 100% confidence The document is a press release dated August 27, 2024, announcing that IBA has signed a Memorandum of Understanding (MOU) with the University of Pennsylvania Health System for the installation of two Proteus®ONE proton therapy solutions. It includes quotes from the CEO and a Professor, and concludes with 'Press release | 27/08/2024'. This format strongly indicates a general corporate announcement regarding a significant business event (a major contract/deal). Since there is no specific category for 'Business Contract Announcement' and it is not a formal regulatory filing like 10-K, ER, or IR, it falls best under the general regulatory/corporate announcement category, which is RNS (Regulatory Filings) as the fallback for miscellaneous corporate news that isn't covered by the more specific codes (like MANG, CAP, or TAR). Given the document length (4410 chars) and content, it is the announcement itself, not a report publication announcement (RPA).
2024-08-27 English
240827-IBA-2ProteusONE-Upenn-FR.pdf
Regulatory Filings Classification · 95% confidence The document is titled with a date (August 27, 2024) and contains sections like 'Communiqué de presse' (Press Release) and contact information for Investor Relations and Corporate Communication. The content describes a significant business agreement (signing a Memorandum of Understanding for two Proteus®ONE systems) rather than periodic financial results (ER, IR), management changes (MANG), or shareholder voting (DVA). This type of announcement, detailing a major contract or strategic development, is typically classified as a general regulatory announcement or press release that doesn't fit a more specific financial reporting code. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, material corporate news releases that are not explicitly defined elsewhere, although 'CAP' (Capital/Financing Update) is sometimes used for major contract wins, RNS is more appropriate for a general press release format.
2024-08-27 French

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.